Associazione Italiana per lo Studio del Pancreas
Quick facts
Phase 3 pipeline
- long-course chemotherapy · Oncology
Long-course chemotherapy involves administering chemotherapy drugs over an extended period to target and kill cancer cells. - PAXG · Oncology
PAXG is a drug that targets the PD-1 receptor. - short-course chemotherapy
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Associazione Italiana per lo Studio del Pancreas portfolio CI brief
- Associazione Italiana per lo Studio del Pancreas pipeline updates RSS
Frequently asked questions about Associazione Italiana per lo Studio del Pancreas
What is Associazione Italiana per lo Studio del Pancreas's pipeline?
Associazione Italiana per lo Studio del Pancreas has 3 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include long-course chemotherapy, PAXG, short-course chemotherapy.
Related
- Sector hub: All tracked pharma companies